Business
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly infected diabetic foot ulcers (iDFU) designed to reduce the risk of antimicrobial resist
About this update from Lakewood-amedex Biotherapeutics Inc.
[{"type":"text","content":"Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial ","length":109,"tagName":"p"},{"type":"text","content":"SARASOTA, Fla., May 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly infected diabetic foot ulcers (iDFU) designed to reduce the risk of antimicrobial resistance (AMR).","length":566,"tagName":"p"},{"type":"image","alt":"Lakewood-Amedex Biotherapeutics Inc. (PRNewsfoto/Lakewood-Amedex Biotherapeutics Inc.)","displaySize":"","headline":null,"caption":"Lakewood-Amedex Biotherapeutics Inc. (PRNewsfoto/Lakewood-Amedex Biotherapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":265,"url":"https://media.zenfs.com/en/prnewswire.com/fdc26168a77475cab607f9d367d14d43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/blfhaGRBqtvusCvNb93wvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2Nw--/https://media.zenfs.com/en/prnewswire.com/fdc26168a77475cab607f9d367d14d43","width":400,"height":265},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Whfo5bcFUcQ2gj0XvWCiHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNA--/https://media.zenfs.com/en/prnewswire.com/fdc26168a77475cab607f9d367d14d43","width":400,"height":265}},"href":"https://mma.prnewswire.com/media/2618352/Lakewood_Amedex_Biotherapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Company has conducted drug substance (the active ingredient) manufacturing process development for a few members of the Bisphosphocin® class and has completed several multikilogram scale under current Good Manufacturing Practices (cGMP) guidelines with high efficiency. In addition, process development advances have improved the cost of goods and have produced bulk drug substance with enhanced physical chemistry characteristics. The Company has also conducted drug product (the gel formulation) manufacturing process development and multikilogram quantities of the Nu-3 gel formulation h...